Alexion Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to extend the approved indication of Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) to patients who are anti-acetylcholine receptor (AChR) antibody-positive,…
News
News
Researchers Gain Insight Into How Myasthenia Gravis Antibodies Destroy Receptor Vital to Movement
University of Southern California researchers have gained insight into how antibodies connected with a disease known as myasthenia gravis destroy a receptor crucial to movement. Their findings may give scientists clues about how to prevent the disease. The study, “Structural insights into the molecular mechanisms of…
Recent Posts
- Ultomiris lifts quality of life, easing fatigue and brain fog in small study
- Adapting to MG left me feeling disconnected from my body
- MDA Engage: Keynote speaker Mindy Henderson redefines the impossible
- Blood T-cell marker may help flag MG recurrence after thymectomy
- CAR T-cell therapy shows sustained benefits in three gMG patients